Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dermata TherapeuticsDRMAW 26 EV-to-EBITDA is 0.00 as of Sep. 09, 2026. GuruFocus rates DRMAW with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 400 Biotechnology companies, Dermata Therapeutics ranks worse than 249999.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Dermata Therapeutics's enterprise value is $0.00 Mil.
Dermata Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-8.60 Mil. Therefore, Dermata Therapeutics's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for Dermata Therapeutics's EV-to-EBITDA or its related term are showing as below:
DRMAW'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.2 Med: 0 Max: 0
Current: -0.2
DRMAW's EV-to-EBITDA is ranked worse than 100% of 400
companies
in the Biotechnology industry
Industry Median: 13.615
vs DRMAW: -0.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dermata Therapeutics's PE Ratio (TTM) for today is calculated as:
Dermata Therapeutics's share price for today is $0.0183.
Dermata Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Dermata Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DRMAW vs CLGN, RVPH, ADTX: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Dermata Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermata Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dermata Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dermata Therapeutics's EV-to-EBITDA falls into.
Dermata Therapeutics's current Enterprise Value is $0.00 Mil.
Dermata Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermata Therapeutics (DRMAW) has a EV-to-EBITDA of 0.00 as of Sep. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dermata Therapeutics. According to the industry distribution chart, Dermata Therapeutics ranks #999999 out of 400 companies in the Biotechnology industry.
Is Dermata Therapeutics' EV-to-EBITDA too high?
Dermata Therapeutics' current EV-to-EBITDA is 0.00. Based on the distribution chart, Dermata Therapeutics ranks #999999 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Dermata Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Dermata Therapeutics' EV-to-EBITDA compare to CLGN and RVPH?
According to the Biotechnology industry distribution chart, Dermata Therapeutics ranks #999999 out of 400 companies for EV-to-EBITDA. This places Dermata Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.62, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dermata Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermata Therapeutics's current EV-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermata Therapeutics stock overvalued right now?
Dermata Therapeutics (DRMAW) has a current EV-to-EBITDA of 0.00. The current EV-to-EBITDA is 0.00. Dermata Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Dermata Therapeutics (DRMAW), the current EV-to-EBITDA is 0.00 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
26GF Score
Get the complete analysis for DRMAW
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRMAW has been successfully added to your 
